Edit |   |
Antigenic Specificity | CD279 (PD-1), Human |
Clone | REAL531 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | n/a |
Format | allophycocyanin (APC) conjugate |
Size | 200 µL |
Concentration | n/a |
Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD279 (PD-1) Antibody, anti-human, APC, REAdye_lease™. Clone REAL531 is an antibody fragment derived from the full CD279 (PD-1) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL531 recognizes the human CD279 antigen, also known as PD-1 (programmed death-1) or PD1. CD279 is a 55 kDa transmembrane protein belonging to the CD28/CTLA-4 family. It is expressed on T cells, B cells, NK cells, activated myeloid cells, and dendritic cells. CD279 is not expressed on naive T cells but induced after activation and expressed on late, differentiated T cells. The ligands PD-L1 (CD274, also known as B7-H1) and PD-L2 (CD273, also known as B7-DC) belong to the B7 immunglobulin superfamily. PD-1 and its ligands mediate inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathology. | PD-1 is used as a marker for angioimmunoblastic lymphoma. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
Immunogen | n/a |
Other Names | PDCD1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 |
Gene, Accession # | n/a |
Catalog # | 130-122-169 |
Price | $470 |
Order / More Info | CD279 (PD-1), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Serriari, N.-E. et al. (2010) B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J Immunol 185: 3140-3148. | Okazaki, T. and Honjo, T. (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19: 813-824. | Fife, B. T. et al. (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann. N. Y. Acad. Sci. 1217: 45-59. | Keir, M. E. et al. (2008) PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704. |